Zymeworks Inc. will participate in investor conferences on December 2 and 3, 2025, in Miami, Florida.
Quiver AI Summary
Zymeworks Inc., a biotechnology company based in Vancouver, announced its participation in two upcoming investor conferences: the Evercore 8th Annual Healthcare Conference and the Citi 2025 Global Healthcare Conference, scheduled for December 2 and 3, 2025, respectively, in Miami, Florida. The company is focused on managing a diverse portfolio of licensed healthcare assets and developing novel biotherapeutics aimed at treating complex diseases like cancer and autoimmune disorders. Their flagship product, Ziihera® (zanidatamab-hrii), a bispecific antibody targeting HER2, is being developed in collaboration with strategic partners. Zymeworks aims to optimize cash flows from its products while advancing innovative therapies through its integrated drug development engine and partnerships with leading biopharmaceutical companies. For more information, Zymeworks directs inquiries to their investor relations and media contacts.
Potential Positives
- Participation in two major investor conferences may enhance Zymeworks' visibility and attract interest from potential investors and partners.
- Zymeworks is advancing a diverse pipeline of novel biotherapeutics, indicating strong innovation and potential growth in the healthcare sector.
- The strategic partnerships with global biopharmaceutical companies may lead to enhanced resources and expertise, improving the company's development capabilities.
Potential Negatives
- None
FAQ
What investor conferences will Zymeworks participate in?
Zymeworks will participate in the Evercore 8th Annual Healthcare Conference and the Citi 2025 Global Healthcare Conference.
When are the conferences scheduled?
The Evercore Conference is on December 2, 2025, and the Citi Conference is on December 3, 2025.
What is the focus of Zymeworks' portfolio?
Zymeworks focuses on managing licensed healthcare assets and developing novel, multifunctional biotherapeutics for difficult-to-treat diseases.
What technology does Zymeworks use for their therapeutics?
Zymeworks utilizes its proprietary Azymetric™ technology to engineer and develop bispecific antibodies like Ziihera® (zanidatamab-hrii).
How can I contact Zymeworks for investor or media inquiries?
Investor inquiries can be directed to Shrinal Inamdar and media inquiries to Diana Papove, both reachable at the provided contact numbers.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ZYME Hedge Fund Activity
We have seen 89 institutional investors add shares of $ZYME stock to their portfolio, and 109 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. removed 2,039,656 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $34,837,324
- MILLENNIUM MANAGEMENT LLC added 988,711 shares (+851.6%) to their portfolio in Q3 2025, for an estimated $16,887,183
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 961,413 shares (+39.1%) to their portfolio in Q3 2025, for an estimated $16,420,934
- ASSENAGON ASSET MANAGEMENT S.A. added 833,994 shares (+169.2%) to their portfolio in Q3 2025, for an estimated $14,244,617
- PERCEPTIVE ADVISORS LLC added 815,389 shares (+63.9%) to their portfolio in Q3 2025, for an estimated $13,926,844
- BRIDGEWAY CAPITAL MANAGEMENT, LLC removed 766,944 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $9,625,147
- VESTAL POINT CAPITAL, LP added 615,000 shares (+53.5%) to their portfolio in Q3 2025, for an estimated $10,504,199
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ZYME Analyst Ratings
Wall Street analysts have issued reports on $ZYME in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B. Riley Securities issued a "Buy" rating on 11/21/2025
- Stifel issued a "Buy" rating on 11/19/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/18/2025
- Citigroup issued a "Buy" rating on 08/11/2025
To track analyst ratings and price targets for $ZYME, check out Quiver Quantitative's $ZYME forecast page.
$ZYME Price Targets
Multiple analysts have issued price targets for $ZYME recently. We have seen 6 analysts offer price targets for $ZYME in the last 6 months, with a median target of $28.5.
Here are some recent targets:
- Mayank Mamtani from B. Riley Securities set a target price of $40.0 on 11/21/2025
- Stephen Willey from Stifel set a target price of $40.0 on 11/19/2025
- Eva Fortea Verdejo from Wells Fargo set a target price of $25.0 on 11/19/2025
- Robert Burns from HC Wainwright & Co. set a target price of $32.0 on 11/18/2025
- Brian Cheng from JP Morgan set a target price of $23.0 on 10/16/2025
- Yigal Nochomovitz from Citigroup set a target price of $22.0 on 08/11/2025
Full Release
VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences:
- Evercore 8 th Annual Healthcare Conference in Miami: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on December 2, 2025, at 10:00 am Eastern Time (ET) in Miami, FL.
- Citi 2025 Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on December 3, 2025 at 3:15 pm ET in Miami, FL.
About Zymeworks Inc.
Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. The Company’s asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera® (zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the early-stage development of innovative medicines. Zymeworks engineered and developed Ziihera® (zanidatamab-hrii), a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Investor inquiries:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
[email protected]
Media inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
[email protected]
